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In Vitro Activities of CG400549, a Novel FabI Inhibitor, against
Recently Isolated Clinical Staphylococcal Strains in Korea
Jong Hwa Yum,1,2,3 Chang Ki Kim,1,2 Dongeun Yong,1,2,3 Kyungwon Lee,1,2,3* Yunsop Chong,1,2
Cheol Min Kim,4 Jeong Mi Kim,4 Seonggu Ro,4 and Joong Myung Cho4
Department of Laboratory Medicine,1 Research Institute of Bacterial Resistance,2 and BK21 Project for
Medical Sciences,3 Yonsei University College of Medicine, and CrystalGenomics, Inc.,4 Seoul, Korea
Received 18 December 2006/Returned for modification 11 January 2007/Accepted 2 April 2007
The in vitro activities of CG400549, a novel FabI inhibitor, were compared to those of linezolid and
commonly used antimicrobials against recent bacterial isolates. CG400549 had an MIC90 of 0.5 g/ml for
Staphylococcus aureus strains and was more potent than either linezolid or vancomycin.
Various antimicrobial resistances among clinical isolates
have become a major problem in recent years. Of particular
concern has been the increasing incidence of methicillin-resis-
tant Staphylococcus spp., vancomycin-resistant Enterococcus
spp., and penicillin-resistant Streptococcus pneumoniae (7).
The recent introduction of the oxazolidinone class of antimi-
crobials into clinical practice represents an important advance
in therapy for infections caused by gram-positive organisms of
multiple antibiotic-resistant strains (3).
The bacterial enoyl-ACP reductase (FabI) is an enzyme
essential for the survival of certain kinds of bacteria (5). Be-
cause FabI shows low overall sequence homology with mam-
malian enzymes, it is a potential target for selective antibacte-
rial action (5, 11). A FabI inhibitor could possess antibacterial
activity against those pathogens in which FabI is the sole enoyl-
ACP reductase (e.g., Staphylococcus aureus, Haemophilus
influenzae, Moraxella catarrhalis, and Escherichia coli), but not
against S. pneumoniae, enterococci, or Pseudomonas aerugi-
nosa, which utilize either FabK or both FabI and FabK (10).
CG400549 (M.W. 340; CrystalGenomics, Inc., Seoul, Korea)
is an inhibitor of FabI (Fig. 1). Therefore, CG400549 could
have antibacterial activities against organisms dependent only
on FabI. An animal study showed that it has potential for the
treatment of staphylococcal infections in mice and rats (4). In
this study, the in vitro activities of CG400549 were compared
with those of other antimicrobial agents against recent clinical
staphylococcal isolates.
(This study was presented in part at the 46th Interscience
Conference on Antimicrobial Agents and Chemotherapy, San
Francisco, CA, 27 to 30 September 2006 [12].)
Nonduplicate clinical isolates were collected in 2005 and
2006 from patients at a Korean tertiary-care hospital. The
species were identified by conventional methods (1) or by using
the Vitek system (bioMerieux SA, Marcy l’Etoile, France).
Staphylococcal strains for which the MIC of CG400549 was2
g/ml were reidentified by using a Vitek GPI kit (bioMerieux
SA) and/or 16S rRNA gene sequencing (8).
The antimicrobial susceptibilities were tested by using the
CLSI agar dilution method or broth microdilution method,
depending on the species (2, 9). CG400549 was provided by
CrystalGenomics, Inc. The agents used in the comparison were
oxacillin, penicillin G, erythromycin, and tetracycline (Sigma
Chemical Co., St. Louis, MO), gentamicin (Chong Kun Dang
Pharmaceutical Co., Seoul, Korea), clindamycin (Korea
Upjohn, Seoul, Korea), sulfamethoxazole and trimethoprim
(Dong Wha Pharmaceutical Co., Seoul, Korea), vancomycin
and tobramycin (Daewoong Pharmaceutical Co., Seoul, Ko-
rea), levofloxacin (Daiichi Pharmaceutical Co., Tokyo, Japan),
linezolid and amikacin (Dong-A Pharmaceutical Co., Seoul,
Korea), cefoxitin and imipenem (Merck Sharp & Dohme,
Rahway, NJ), ciprofloxacin (Bayer Korea Co., Seoul, Korea),
clarithromycin (Hanmi Pharmaceutical Co., Seoul, Korea),
and doxycycline (Pfizer Korea, Seoul, Korea). Staphylococcus
aureus ATCC 29213 and Enterococcus faecalis ATCC 29212
were used as controls in each plate.
In our preliminary study, CG400549 had no activity against
gram-positive bacteria, such as streptococci, enterococci, M.
catarrhalis, Listeria monocytogenes, Nocardia spp., and non-
tuberculous mycobacteria, and gram-negative bacteria, such as
E. coli, Klebsiella pneumoniae, Enterobacter cloacae, Citrobacter
freundii, Serratia marcescens, Morganella morganii, Acineto-
bacter baumannii, P. aeruginosa, Aeromonas spp., Vibrio spp.,
H. influenzae, Campylobacter fetus, Helicobacter pylori, and
Neisseria gonorrhoeae (data not shown).
In many Korean hospitals, the methicillin resistance rates of
S. aureus isolates in 1998 were approximately 70% (6). In the
present study, all isolates of S. aureus were inhibited by 4
g/ml of vancomycin and linezolid and the MIC90s for these
agents were 1 g/ml and 2 to 4 g/ml, respectively (Table 1).
However, all isolates of methicillin-resistant and methicillin-
susceptible S. aureus were inhibited by1 g/ml of CG400549.
The majority of the methicillin-resistant, coagulase-negative
* Corresponding author. Mailing address: Department of Labora-
tory Medicine, Yonsei University College of Medicine, 134 Shinchon-
dong, Seodaemunku, Seoul 120-752, Korea. Phone: 82-2-2228-2446.
Fax: 82-2-313-0908. E-mail: leekcp@yumc.yonsei.ac.kr.
 Published ahead of print on 9 April 2007. FIG. 1. Structure of CG400549, a FabI inhibitor.
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Staphylococcus (MRCNS) isolates were also resistant to most
of the antimicrobial agents tested. All MRCNS and methicil-
lin-susceptible, coagulase-negative Staphylococcus (MSCNS)
isolates were inhibited by 16 g/ml of vancomycin and 4
g/ml of linezolid. The MIC range and MIC90 of CG400549
for MRCNS isolates were 0.12 to 16 g/ml and 4 g/ml, re-
spectively, and for MSCNS isolates, they were 0.5 to 8 g/ml
and 8 g/ml, respectively.
The MRCNS isolates with high CG400549 MICs included
five S. hominis (4 to 16 g/ml), three S. epidermidis (4 to 8
g/ml), two S. haemolyticus (2 to 16 g/ml), one S. saprophyti-
cus (8 g/ml), and one S. sciuri (4 g/ml) isolate; the MSCNS
isolates with high CG400549 MICs included three S. simulans
(4 to 8 g/ml), two S. haemolyticus (2 to 4 g/ml), two S.
hominis (4 g/ml), and one S. epidermidis (8 g/ml) isolate.
In conclusion, CG400549 is a FabI inhibitor with high in
vitro activity against both methicillin-susceptible and -resistant
S. aureus strains, including multidrug-resistant strains.
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Erythromycin 0.25–128 128 128 5 0 95
Clindamycin 0.06–128 128 128 12 0 88
Cotrimoxazole 0.06–64 0.06 16 67 — 33
Gentamicin 0.5–128 128 128 10 2 88
Levofloxacin 0.25–128 16 128 7 0 93
Tetracycline 0.12–128 64 128 25 0 75
Oxacillin 32–128 128 128 0 — 100
Vancomycin 0.5–2 1 1 100 0 0
Methicillin-susceptible S. aureus (60)
CG400549 0.12–1 0.5 0.5 — — —
Linezolid 2–4 4 4 100 — —
Erythromycin 0.25–128 0.5 128 88 0 12
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Linezolid 0.5–4 1 2 100 — —
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Tetracycline 0.12–128 2 128 67 2 31
Oxacillin 0.5–128 32 128 0 — 100
Vancomycin 0.5–16 1 2 99 1 0
Methicillin-susceptible, coagulase-negative
Staphylococcus spp. (36)
CG400549 0.5–8 0.5 8 — — —
Linezolid 0.5–2 1 2 100 — —
Erythromycin 0.12–128 0.25 128 78 6 17
Clindamycin 0.06–128 0.12 0.25 97 0 3
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a S, susceptible; I, intermediate; R, resistant; —, CLSI breakpoint is not available.
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